Y-mAbs is committed to developing innovative immunotherapies to overcome cancer

Y-mAbs isn’t like every other biopharmaceutical company. It was founded by Thomas Gad, President, Head of Business Development and Strategy, and, more importantly, the father of Daniella, a high-risk neuroblastoma survivor. After years of therapy and searching for an effective option around the world, his daughter received treatment from Memorial Sloan Kettering Cancer Center. Since then, Mr. Gad has envisioned applying for regulatory approval to help other patients and their families get access to products currently under study and development that were used to treat his daughter. Along with Mr. Gad, the leadership at Y-mAbs is distinguished by their professional commitments to creating effective treatments—with many individuals having spent years working in the field of immunotherapy and drug development.

Y-mAbs has an advanced pipeline of antibody immunotherapies, which are currently being investigated in ongoing clinical trials, that may someday help patients fight cancer.

Patient and family resources

Patient ResourcesY-mAbs is currently conducting ongoing clinical trials in rare diseases, including CNS/LM metastases in neuroblastoma with primary or refractory disease in bone and/or bone marrow, and others that your child may be able to participate in, based on eligibility.

Access to Clinical Trials

Learn about access to Y-mAbs clinical trials

Request information

Online resources

Patient ResourcesAlong the journey to finding treatment, there are many resources that can be helpful to you, your child, and your family. Here are a select few that can help better explain certain conditions and how to cope with them. Your physician is your primary source for medical questions regarding treatment and your care, and these resources should not be considered substitutes for professional medical guidance.

About neuroblastoma

For families and patients

Advocacy groups